Ophthalmology is the branch of medicine that deals with the anatomy, physiology and diseases of eye. Recent advancements in genetics and stem cell biology have brought number of changes to the Ophthalmology Therapeutics Industry.
Asia Pacific Ophthalmology Therapeutics is driven by the growing prevalence for vision impairment. According to a recent update by WHO the prevalence of visual impairment is nearly 285 million globally. Of these 246 million people have moderate to severe visual impairment. South-East Asia and Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of Industry include, increasing awareness about the importance of detecting ophthalmic diseases as early as possible and the availability of efficient diagnostic tools. However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the Industry.
Asia Pacific Ophthalmology Therapeutics is broadly categorized into Indication and End User. Based on indication the Industry is segmented into Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis. Glaucoma is the largest indication segment accounting for a share of approximately XX%. On the basis of End User, the Industry is segmented into Hospitals, Eye Clinics, Diagnostic Centres and Patients.
Geographically, Asia Pacific Ophthalmology therapeutics Industry is segmented into various regions namely China, India, Japan, South Korea and Australia. Asia Pacific is the fastest growing region with a CAGR of xx% during the forecast period. Within Asia Pacific, Japan is the largest Industry for Opthalmology therapeutics accounting for a share of approximately 45% followed by China
Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche, Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals are the major companies covered in the report.
Key Points from Table of Contents Overview Executive Summary Key Inferences New Developments Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) Asia Pacific Ophthalmology Therapeutics Industry: Segmentation By Indication o Glaucoma o Dry Eye Syndrome o Diabetic Retinopathy o Retinal Vein Occlusion o Age-Related Macular Degeneration (AMD) o Macular Edema o Allergic Conjunctivitis By End User o Hospitals o Eye Clinics o Diagnostic Centers o Patients Geographical Analysis China India Japan South Korea Australia Strategic Analysis PESTLE analysis Porters Five analysis Industry Leaders' Analysis Competitive Landscape
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.